Numerous diagnostic tests based on prostate‐specific antigen (PSA) have been developed so far to improve early detection of prostate cancer; however, minimally invasive tests with better specificity and sensitivity are still needed to further improve diagnosis and risk stratification. This evidence concerns the gene PSAT1 and Familial prostate cancer.